BioCryst Reports Sustained Benefits Of Berotralstat in Children, Adolescents, And Adults With Hereditary Angioedema
Sector Update: Health Care Stocks Lean Lower Premarket Friday
BioCryst Pharmaceuticals Receives INVIMA Approval for ORLADEYO in Colombia for Prophylaxis of Hereditary Angioedema Attacks
Express News | Orladeyo® (Berotralstat) Approved in Colombia
Sector Update: Health Care Stocks Advance Premarket Friday
Netherlands Approves BioCryst Pharma's ORLADEYO For Hereditary Angioedema Prevention, Expanding National Access Across Europe
Press Release: BioCryst Achieves Reimbursement for ORLADEYO Across All Major European Countries
BioCryst Pharmaceuticals (BCRX) Is a Great Momentum Stock: Should You Buy?
Express News | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
Express News | Biocryst Pharmaceuticals Announced New Data Which Highlights The Reduction In The Percentage Of Days With Hereditary Angioedema (HAE) Symptoms Among Young Children Initiating Berotralstat In The Apex-P Trial, And The Broad Safety And Efficacy Outcomes...
BioCryst to Present at Upcoming Investor Conferences
Market Chatter: Singapore Discussing Zero Tariffs on Pharmaceutical Exports to US
Sector Update: Health Care Stocks Flat to Higher Premarket Friday
BioCryst Says Orladeyo Prompted 'Significant' Drop Hereditary Angioedema Attacks in Study
Singapore Eyes Preferential Tariff Deal With US For Pharmaceutical Exports
BioCryst Pharma Presents New Real-World Evidence Showing ORLADEYO Delivers Sustained HAE Attack Reduction in Adolescents & Severe Cases
Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $17
BioCryst Gets Speedy FDA Review of Pediatric Use of Orladeyo